Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
DISHMAN, Worry on Cash Flow Continues

DISHMAN, Worry on Cash Flow Continues - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-14 09:09:01 - DISHMAN, Worry on Cash Flow Continues - a new market research report on companiesandmarkets.com

Dishman Q3FY13 result was below than our estimates due to lower sales of Dishman Netherlands, resulting in 440 bps decline in EBITDA margins on sequential basis. Revenue of Dishman Netherlands declined by 14% as it is going through complete renovation and is expected to be operational by Q3FY14. Total revenue grew by 19% due to higher growth of Carbogen Amcis (up by 32%). Impact of forex remained neutral to the bottom-line.

Going forward in FY14 CRAMS as well as MM both may witness a modest growth. CRAMS will be impacted by decline in Eprosartan contractual demand, that would be more than offset by new contracts (API supply for an oncology drug and Tuberculosis drug to Astellas and JNJ respectively), while current

 

 

renovation at Dishman Netherlands will slowdown the growth momentum of marketable molecule (MM) business. Company expects FY14 revenue to grow by 12-13% supported by ~Rs.800-1000m from generic business.

With Scheduled debt repayment of ~Rs.1b and Rs.1.5b in CY 2013 and CY 2014 respectively coupled with lower visibility of free cash flow generation, we continue to remain concerned about the fate of highly levered (operating and financial) business model of Dishman. The fact that the company is likely to repay the debt of ~Rs.1b in 2013 from the proceeds of the sale of SEZ land clearly signifies that company is not generating sufficient free cash flow to service its debt.

As the proposed sale of SEZ land has eliminated immediate debt repayment concerns (Rs.1b), we increase our target price from Rs.47 to Rs.62, while accounting for lower capax (Rs.500m) in FY14. We retain our underperform rating on Dishman.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com